Lantheus Holdings, Inc.
http://www.lantheus.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lantheus Holdings, Inc.
EMA Backs EU Approval For Ztalmy & Pylclari; Roches Withdraws EU Filing For AMD Implant
Two new products, one for epilepsy and the other for prostate cancer, were recommended for EU approval during the latest monthly meeting of the European Medicines Agency’s human medicines committee, the CHMP.
Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium And Macropa Platforms
Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
Company Information
- Industry
- Services
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
- MRI, NMR
- Ultrasound
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice